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Heart Failure With Preserved Ejection Fraction
A Meta-Analysis
Objectives We sought to determine whether pharmacologic interventions changed exercise capacity, diastolic function, and
mortality in a meta-analysis of trials in heart failure with preserved ejection fraction.
Background Treatment strategies for heart failure with preserved ejection fraction remain unproven despite several large-
scale trials.
Methods Trials were included in the systematic review where clear comparisons between trial drug and diuretic or pla-
cebo were available. Exercise tolerance was assessed by treadmill time, and changes in diastolic function were
quantified by transmitral flow (E/A ratio). The primary outcome was all-cause mortality. Weighted mean differ-
ences (MDs) and relative risks (RRs), along with their corresponding 95% confidence intervals (CIs), were com-
puted using random-effects models for continuous and dichotomous variables, respectively. The impact of poten-
tial covariates was assessed by meta-regression.
Results Data from 53,878 patients enrolled in 30 published reports were collated, including 18 randomized controlled
trials (n  11,253) and 12 observational studies (n  42,625). In the randomized controlled trials, exercise tol-
erance was improved by combined therapy (n  183; weighted MD  51.5; 95% CI: 27.3 to 75.7; p  0.001),
whereas E/A ratio was not (n  472; weighted MD  0.01, 95% CI: 0.02 to 0.02; p  0.54) even after ac-
counting for baseline E/A (p  0.87). Over a mean follow-up of 18.6 months, all-cause mortality was not im-
proved by therapy in randomized controlled trials (RR: 0.99, 95% CI: 0.92 to 1.06; p  0.70), despite accounting
for baseline ejection fraction (p  0.72). In observational reports, there was a reduction in all-cause mortality
with therapy in the unadjusted analyses (RR: 0.80, 95% CI: 0.66 to 0.97; p  0.27), but not after adjustment for
clinical and demographic data (RR: 0.93, 95% CI: 0.84 to 1.02; p  0.10).
Conclusions Pharmacotherapy of heart failure with preserved ejection fraction demonstrates a quantifiable improve-
ment in exercise tolerance but not mortality. (J Am Coll Cardiol 2011;57:1676–86) © 2011 by the
American College of Cardiology FoundationEstimated costs associated with the heart failure (HF) epi-
demic have been steadily increasing over previous decades and
now stand at $39.2 billion per year in the United States (1),
with similar trends reported in other developed countries (2,3).
Hospitalizations for HF have tripled over the past 3 decades
(4), with important contributions from the aging population
nd improved treatments of underlying conditions (5). Impor-
antly, up to one-half of all HF cases demonstrate normal left
entricular (LV) systolic function (6) and are subsequently
abeled as having heart failure with preserved ejection fraction
See page 1687
(HFpEF). In contrast to patients with systolic heart failure
(SHF), those with HFpEF are generally older, more often
female, and have a higher prevalence of hypertension, LV
hypertrophy, diabetes mellitus, and atrial fibrillation (6–9), yet
re at similar risk of adverse events as patients with SHF (6–8).
lthough there has been increasing success of pharmacological
herapy to improve outcomes of SHF, prognosis for HFpEF
emains unchanged (7), with no individual large-scale random-
zed controlled trial (RCT) demonstrating significant treat-
ent benefits.
Despite the failure to provide effective pharmacotherapyor improving primary endpoints of mortality, there are anumber of trials in HFpEF demonstrating a range of
secondary benefits in response to various agents. As patients
with HFpEF are often older than their SHF counterparts,
these findings may provide support for therapies that im-
prove symptoms, rather than mortality. However, to date,
there are no data combining experiences from published
HFpEF trials. In this meta-analysis of pharmacological
trials in HFpEF, we hypothesized that since previous
studies have been neutral, combining them might bring a
different result for treatment effects not only on mortality
but also on exercise tolerance and diastolic function. The
detection of a response beyond those witnessed in individual
studies might inform clinical practice and future studies.
Methods
Search strategy. A search of PubMed, the Cochrane Con-
trolled Trials Registry, and the U.S. Clinical Trials databases
was performed using these key terms: heart failure, diastolic
heart failure, heart failure normal ejection fraction, heart failure
preserved ejection fraction. From these lists, published clinical
trials investigating the effects of various interventions on
HFpEF were identified, for both interventional and observa-
tional studies. To ensure the identification of all relevant trials,
the reference lists of these articles were then scrutinized to
further identify studies pertinent to the topic. In some cases,
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Meta-Analysis of Therapy in HFpEF April 19, 2011:1676–86subgroup analyses in HFpEF were
performed within trials primarily
investigating SHF. These trials
were also identified through the
various search strategies. The
search strategy, study selection and
analysis adhered to QUOROM
guidelines for meta-analyses (10).
Study selection. Studies included
in this analysis were required to
describe the method of HF diag-
nosis, report LV ejection fraction
(EF), clearly define intervention
and control groups, and provide
information on primary endpoints
such as mortality, hospitalization,
or other outcomes such as exercise
capacity, diastolic function, and
quality of life. This review incor-
porates both interventional RCTs
and observational studies. Pro-
spective RCTs were required to
stipulate pre-specified analyses and
Figure 1 Flow Diagram for Inclusion of Studies in Meta-Analysi
Detailed evaluation was performed on 49 of 110 potentially relevant articles. Afte
12 observational studies were entered into the meta-analysis. HFpEF  heart failu
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin-
receptor blocker
CI  confidence interval
E/A  ratio of early to late
transmitral flow
EF  ejection fraction
HF  heart failure
HFpEF  heart failure with
preserved ejection fraction
HR  hazard ratio
LV  left ventricular
MD  mean difference
RCT  randomized
controlled trial
RR  relative risk
SHF  systolic heart failurereport baseline and follow-up data for both intervention and
control groups. Observational studies were included where a
specific diagnosis of HFpEF was made, and where EF was
quantified. Trials were not included where EF could not be
accurately substantiated or where data pertinent to the analysis
(i.e., outcomes) were not available.
Data collation. Clinical, echocardiographic, and outcome
data were extracted from individual studies by 2 experienced
abstractors (D.J.H. and S.H.A.) and entered into an electronic
database. Where available, these data included group numbers,
primary and secondary endpoints, information on the diagnos-
tic criteria for HFpEF, etiology, EF, clinical characteristics,
age, sex, and length of follow-up. For multiple articles pub-
lished from a single dataset, the largest study with primary
findings or the more HFpEF-specific subgroup analysis was
assessed. Despite inclusion in a common report, studies includ-
ing 1 treatment arm were considered as individual trials,
here comparison could be made between control and inter-
ention groups. Data from the individual trial arms are cited
hroughout this analysis.
utcome measures. Information on outcomes was ex-
racted from individual studies containing a formal analysis
sions, 18 randomized controlled trials (RCTs) and
preserved ejection fraction.s
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April 19, 2011:1676–86 Meta-Analysis of Therapy in HFpEFof prognosis. Endpoints were tallied to identify the out-
comes common to most reports, with RCTs and observa-
tional studies analyzed separately. For this analysis, the
primary outcome measure was all-cause mortality in indi-
vidual analyses of RCTs and observational studies using
hazard ratios (HRs) and 95% confidence intervals (CIs).
Secondary endpoints included assessment of diastolic func-
tion quantified by the ratio of early to late diastolic trans-
mitral flow (E/A ratio), and severity of symptoms deter-
mined by exercise tolerance (exercise capacity graded by
treadmill time). Other outcome data were extracted, but in
many cases, inconsistencies in reported outcomes prevented
pooled analysis. Only studies reporting at least 1 of these
endpoints were included in the analysis.
Statistical analysis. For the primary (dichotomous) out-
come, relative risks (RRs) and 95% CI were computed using
random-effects models (11). The weighted MD and corre-
sponding 95% CI were computed using random-effects models
for continuous variables. Between-studies heterogeneity was
assessed using the Cochran Q test (based on the pooled RR by
Mantel-Haenszel), as well as by measuring inconsistency (I2
[the percentage of total variance across studies attributable to
heterogeneity rather than chance]) of treatment effects across
trials (12). We used Begg’s funnel plot to assess for publication
bias for the primary outcome of all-cause mortality (13).
Study Characteristics for Randomized Controlled TrialsTable 1 Study Characteristics for Randomized Controlled Trials
Trial or First Author
(Ref #) Arm Year Entry EF
Intervention
Group(s) (n) G
ALLHAT* (31) A 2008 50% 98
B 110
C 79
CHARM-P* (18) 2003 40% 1,514
DIG* (15) 2006 45% 492
Hong Kong DHF*† (16) A 2008 45% 56
B 45
I-PRESERVE* (17) 2009 45% 2,067
PEP-CHF* (19) 2006 WMI1.4
(EF40%)
424
SENIORS* (20, 22) 2009 35% 380
SENIORS Echo† (21) 2006 35% 27
SWEDIC† (23) 2004 WMI1.2
(EF45%)
47
V-HeFT I* (24) A 1996 35% 52
B 50
V-HEFT II* (24) 1996 35% 115
Aronow et al.* (25) 1997 40% 79
Aronow et al.†‡ (26) 1993 50% 10
Mottram et al.†‡ (27) 2004 50% 15
Nodari et al.†‡ (28) 2003 50% 13
Hung et al.†‡ (32) 2002 50% 15
Setaro et al.†‡ (29) 1990 45% 20
Kitzman et al.‡ (30) 2010 50% 35Endpoints: *mortality, †exercise capacity, ‡diastolic function. §Cross-over design where patients comple
ACE  angiotensin-converting enzyme; EF  ejection fraction; WMI  wall motion index.Quality assessment of the analyzed RCTs was performed by
Jadad’s method (14). Since the majority of included studies (13
of 14 treatment arms) had a quality score of 4/4 for mortality,
suggesting high quality, a formal quality score and/or weight-
ing of results was not calculated. For exercise capacity, only 1
study had nonblinded assessment of outcome. As a number of
important baseline variables differed between studies (e.g., EF
ranged from 35% to 50%), meta-regression was used to
ssess the influence of potential covariates (i.e., baseline vari-
bles) on the outcome measures. All therapy types were initially
rouped to show an overall effect of treatment versus placebo
control). Some studies compared a treatment agent to stan-
ard therapy (for example, diuretic), and in these cases,
tandard care was accepted as the control group for compari-
on. Data were also analyzed by each drug class (e.g.,
ngiotensin-converting enzyme inhibitors [ACEI] and
ngiotensin-receptor blockers [ARB], vasodilators, and
-blockers, as well as a combination of chronotropic agents,
including digoxin, verapamil, and -blockers) to show the
ffect of similar therapies. Forest plots were constructed to
raphically describe the overall effects of intervention versus
lacebo. Statistical analysis was performed using standard
oftware packages (STATA version 10.0, College Station,
exas; and SPSS version 17.0, SPSS Inc., Chicago, Illinois)
ith 2-tailed p values, and p  0.05 considered significant.
l
n)
Total
Group (n) Intervention Control
Follow-Up
(Months)
215 Lisinopril Chlorthalidone 20.9
110 Amlodipine
145 Doxazosin 18.6
3,023 Candesartan Placebo 36.6
988 Digoxin Placebo 37
106 Irbesartan  diuretic Diuretic only 12
45 Ramipril  diuretic
4,128 Irbesartan Placebo 49.5
850 Perindopril Placebo 25.2
752 Nebivolol Placebo 21
61 Nebivolol Placebo 12
97 Carvedilol Placebo 6
124 Prazosin Placebo 27.6
50 Hydralazine/isosorbide
dinitrate
218 Enalapril Hydralazine/
isosorbide dinitrate
30
158 Propanolol  diuretic
 ACE
Diuretic  ACE only 12
21 Enalapril  diuretic Diuretic only 3
30 Spironolactone Placebo 6
26 Nebivolol Atenolol 6
30§ Verapamil Placebo 3
40§ Verapamil Placebo 1.25
71 Enalapril Placebo 12Contro
roup (
117
66
1,509
496
50
2,061
426
372
34
50
72
103
79
11
15
13
15
20
36ted both arms of study.
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A total of 30 published reports investigating treatment
options in 53,878 patients with HFpEF met the inclusion
criteria (Fig. 1). There were 11,253 patients enrolled in 18
RCTs (15–32), with a mean follow-up of 18.6 months
(range 6 weeks to 59.5 months). There were an additional
42,625 patients enrolled in 12 observational studies
(33– 44). When trials were separated into individual
treatment arms, there were a total of 45 individual
treatment groups (22 RCTs, 23 observational) compared
with control (placebo/usual care). Formal analysis con-
firmed there was no publication bias (RCTs, p  0.13;
observational studies, p  0.32). Subject characteristics
of patients enrolled in RCTs and observational studies
are presented in Tables 1 and 2, respectively.
ffect of therapy on mortality. The effect of therapy on
utcomes in displayed in Table 3. Combined therapy from
4 treatment options in RCTs, did not improve outcome
RR: 0.99, 95% CI: 0.92 to 1.06; p  0.70) (Fig. 2), even
fter accounting for baseline EF with meta-regression (p 
Study Characteristics for Observational StudiesTable 2 Study Characteristics for Observational Studies
Trial/First Author
(Ref. #) Arm Year
Entry
EF
Intervention
Group (n)
Cont
Group
OPTIMIZE-HF,
Hernandez et al. (41)
2009 40% 1,621 2,532
OPTIMIZE-HF,
Fonarow et al. (40)
A 2007 40% 48% 52
B 60% 40
Shamagian et al. (35) A 2006 50% 210 206
B 23.6% 76
C 66.1% 33
D 31.0% 69
Dauterman et al. (34) 2001 40% 48% 52
Dobre et al. (37) 2007 40% 227 216
Fukuta et al. (36) A 2005 50% 68 69
B 75 62
C 68 69
D 37 100
Tribouilloy et al. (39) 2008 50% 165 193
Shah et al. (38) A 2008 50% 2,313 11,220
B 6,413 7,120
C 4,562 8,971
Ouzounian et al. (42) 2009 50% — —
Philbin et al. (33) 2000 50% 137 165
Sueta et al. (44) A 2003 50% 399 361
B 172 588
C 235 525
Ahmed et al. (43) 2002 40% 62 176ARB  angiotensin-receptor blocker; other abbreviations as in Table 1..72). When analyzed by drug class, no individual therapy
mproved outcome compared with placebo (Table 3).
Observational studies reported both unadjusted and ad-
usted HRs. In 12 treatment arms with unadjusted analysis
Fig. 3A), combined therapy improved mortality (RR: 0.80,
5% CI: 0.66 to 0.97; p  0.027). On individual analysis,
oth ACEI/ARBs and -blockers improved outcome in
nadjusted data (Table 3). After adjusting for a range of
emographic and clinical features, combined therapy in 23
tudies failed to demonstrate a significant mortality benefit
RR: 0.93, 95% CI: 0.84 to 1.02; p  0.103) (Fig. 3B).
ndividual therapies (-blockade or ACEI/ARB) also had
no effect on adjusted mortality (Table 3).
Effect of therapy on exercise capacity. Overall, exercise
capacity, reported in 183 patients enrolled in 6 RCTs, was
significantly improved by combined treatment (weighted
MD 51.5, 95% CI: 27.3 to 75.7; p  0.001) (Fig. 4). By
drug class, vasodilator therapy and chronotropic agents
improved exercise capacity (Table 2). There were no differ-
ences in pre-intervention exercise time for combined and
individual therapies (p  0.2 for all).
Total
Group (n) Intervention Study Type
Follow-Up
(Months)
4,153 -blockers Retrospective study of
registry-based dataset
12
21,149 ACE inhibitors Retrospective study of
registry-based dataset
2–3
-blockers
416 ACE inhibitors Prospective follow-up study 144
-blockers
Diuretics
Calcium-channel
antagonists
430 ACE inhibitors Retrospective study of
Medicare registry
dataset
12
443 -blockers Prospective follow-up study 25
137 Statins Study of registry-based
dataset
24
ARB/ACE inhibitors
-blockers
Calcium-channel
antagonists
358 ACE inhibitors Population-based registry
follow-up study
60
13,533 Statins Retrospective study of
Medicare registry
dataset
36
ACE inhibitors
-blockers
706 Statins Trial-based registry follow-
up study
60
312 ACE inhibitors Study of registry-based
dataset
6
760 ARB/ACE inhibitors Retrospective study of
Medicare registry
dataset
12
-blockers
Digoxin
238 ACE inhibitors Retrospective study of
Medicare registry
dataset
48rol
(n)
%
%
.4%
.9%
.0%
%
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April 19, 2011:1676–86 Meta-Analysis of Therapy in HFpEFEffect of Therapy on Mortality, Diastolic Function, and Exercise CapacityTable 3 Effect of Therapy on Mortality, Diastolic Function, and Exercise Capacity
RR/MD 95% CI p Value
p Value After
Meta-Regression
Mortality in RCTs
Combined therapy 0.99 0.92 to 1.06 0.699 0.722
ACEI/ARB 1.02 0.94 to 1.12 0.603 0.952
Vasodilators 1.02 0.93 to 1.11 0.694 —
Chronotropic agents 0.91 0.78 to 1.07 0.248 0.712
Mortality in observational studies (unadjusted data)
Combined therapy 0.80 0.66 to 0.97 0.027
ACEI/ARB 0.74 0.58 to 0.96 0.022
-blockers 0.86 0.77 to 0.96 0.006
Mortality in observational studies (adjusted data*)
Combined therapy 0.93 0.84 to 1.02 0.103
ACEI/ARB 0.95 0.79 to 1.13 0.544
-blockers 0.93 0.83 to 1.04 0.196
Diastolic function in RCTs (post-intervention E/A ratio)
Combined therapy 0.01 0.03 to 0.02 0.541 0.868
ACEI/ARB 0.01 0.04 to 0.02 0.470 0.477
Vasodilators 0.01 0.04 to 0.02 0.351 0.979
Chronotropic agents 0.03 0.03 to 0.09 0.387 0.335
Exercise capacity in RCTs (post-intervention treadmill time, s)
Combined therapy 51.5 27.3 to 75.7 0.001
ACEI/ARB
Vasodilators 48.3 20.5 to 76.2 0.001
Chronotropic agents 61.0 12.3 to 109.7 0.014
*Risk ratios generated from adjusted hazard ratios reported in trials after statistical consideration of demographic, clinical, or echocardiographic differences between groups.
ACEI  angiotensin-converting enzyme inhibitor; CI  confidence interval; MD  mean difference (weighted, continuous data); RCT  randomized controlled trial; RR  relative risk (dichotomous
variables); other abbreviations as in Tables 1 and 2.Figure 2 Forest Plot Showing Effect of Treatment on Mortality in RCTs
There is no significant effect on mortality (relative risk: 0.99; 95% confidence interval [CI]: 0.92 to 1.06) in randomized controlled trials (RCTs),
and the results appear homogeneous.
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Meta-Analysis of Therapy in HFpEF April 19, 2011:1676–86Effect of therapy on diastolic function. The E/A ratio was
the most common diastolic function variable, reported in 472
patients enrolled in 9 RCTs. There were no baseline differ-
ences in pre-intervention E/A ratio (p  0.1 for all). Overall,
here was no effect of treatment on the E/A ratio (weighted
D 0.01, 95% CI: 0.03 to 0.02; p  0.54) (Fig. 5), even
fter accounting for baseline E/A ratio by meta-regression
p  0.87). Separation of trials into respective drug classes—
Figure 3 Forest Plots of Unadjusted Data of Treatment Effect o
Observational Studies and Adjusted Data of Treatmen
(A) Forest plot of unadjusted data showing effect of treatment on mortality in obs
0.79, 95% CI: 0.66 to 0.97), but with greater heterogeneity than among the RCTs
There is no significant effect on mortality (relative risk: 0.93; 95% CI: 0.84 to 1.02CEI/ARB, -blockers, vasodilators, or combined chrono-tropic agents—did not demonstrate any improvement in the
E/A ratio compared with control, even after meta-regression to
correct for baseline diastolic function (p  0.3 for all).
Discussion
In contrast to evidence-based therapy for SHF, treatment
options for patients with HFpEF remain unproven.
rtality in
ct on Mortality in RCTs
nal studies. There appears to be a favorable effect on mortality (relative risk:
orest plot of adjusted data showing effect of treatment on mortality in RCTs.
there is greater heterogeneity than in the RCTs. Abbreviations as in Figure 2.n Mo
t Effe
ervatio
. (B) F
), andCurrent recommendations support the treatment of un-
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April 19, 2011:1676–86 Meta-Analysis of Therapy in HFpEFderlying etiologies (5), although the associated benefits of
these therapies on hard endpoints are anticipated rather
than proven in this group. This analysis adds to existing
literature by providing the first report pooling data from
major trials and demonstrates a number of important
issues. The major finding of this study was the improve-
ment of exercise capacity in the absence of improvements
in diastolic function or benefits on the primary outcome
Figure 4 Forest Plot Showing Treatment Effect on Exercise Ca
There appears to be a significant effect on exercise capacity (weighted difference
and the results appear homogeneous. Abbreviations as in Figure 2.
Figure 5 Forest Plot Showing Treatment Effect on Diastolic Fu
There is no significant effect on diastolic function (E/A ratio [weighted difference 
and there is some heterogeneity of the results. Abbreviations as in Figure 2.of mortality. As patients with HFpEF are usually older
than patients with SHF, improvement of symptoms,
rather than mortality rates, may present an important
consideration for therapeutic strategies in this patient
cohort. With only 6 trials (183 patients) reporting the
effect of drug therapy on exercise capacity, this endpoint
requires further investigation as it is a major determinant
of quality of life in patients with HF.
y in RCTs
; 95% CI: 27.29 to 75.65) in RCTs,
n in RCTs
95% CI: 0.03 to 0.02]) in RCTs,pacit
51.47nctio
0.01;
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Meta-Analysis of Therapy in HFpEF April 19, 2011:1676–86Criteria for HFpEF. This analysis highlights important
issues regarding patient selection and characterization of
HFpEF. Our analysis was limited by the widespread dis-
parity in patient selection criteria in many of the trials
investigating HFpEF. Many of the RCTs collated in this
analysis were planned and conducted before objective crite-
ria were developed (45–48). Though not proven, it is
possible that more uniform criteria may improve the ability
of trials to reach pre-specified endpoints. Historically con-
sidered a diagnosis of exclusion, recent guidelines suggest
employing objective clinical and imaging criteria for
HFpEF that include protocols for excluding HFpEF (48).
The poor correlation between published HFpEF criteria
and the selection process employed in large clinical trials
was highlighted in a recent analysis of HFpEF trials (49). In
this review, 40% of major clinical trials required a normal
EF (50%), and only 7 of the 21 major trials required
evidence of diastolic dysfunction. Many trials reporting
interventions in HFpEF required an EF 35%—a thresh-
old generally not considered “preserved.” These observations
support the need for adherence to strict diagnostic criteria so
that a more homogenous group can be identified to avoid
recruiting patients with unsubstantiated HFpEF (50).
In addition, many of the observational trials included in
this meta-analysis analyzed HFpEF as a subgroup within
SHF trials. That much of the evidence used for treatment of
HFpEF has been drawn directly from experience with SHF
may partly explain the lack of available HFpEF-specific
treatment options. In general, the results of this analysis
suggest that the current evidence base not only demon-
strates a lack of effective treatment strategies in HFpEF, but
also that the use of standard diagnostic criteria and pre-
specified analyses may facilitate the investigation of treat-
ment options for these patients.
Current therapy and future directions in HFpEF therapy.
Current recommendations for the treatment of HFpEF
primarily include control of underlying comorbidities such
as hypertension, ventricular rate in atrial fibrillation, pulmo-
nary congestion, and peripheral edema (5,51). Subsequent
considerations are the identification (5) and treatment of
coronary artery disease (6,7) and the restoration of normal
sinus rhythm in atrial fibrillation.
The selection of specific pharmacotherapy would be desir-
able, but remains elusive. Identification of a homogenous
patient group may present better opportunities for interven-
tion. Patients with HFpEF are typically characterized by
multiple comorbidities for which the effective treatment of
underlying conditions remains the primary objective of thera-
peutic intervention. Specifically, impaired ventricular-vascular
coupling, myocardial fibrosis, and uncontrolled hypertension
are emerging areas with the TOPCAT (Treatment of Pre-
served Cardiac function heart failure with an Aldosterone
anTagonist) and ALDO-DHF (ALDOsterone receptor
blockade in Diastolic Heart Failure) trials currently investigat-
ing the role of spironolactone in HFpEF. There are also data
from a small trial of advanced glycation end product breakers,demonstrating promising improvements in diastolic function
and quality of life (52). However, further investigations are
needed and are under way.
Finally, large RCTs have focused on mortality endpoints
in HFpEF. In SHF, mortality endpoints do not correlate
well with change in exercise tolerance or quality of life—
evident in examples of improved survival with limited or no
symptom change (53,54), and symptomatic improvement
without survival benefit (55,56). The results of this analysis
suggest that a similar dissociation between endpoints may
be present in HFpEF, and that changes in exercise capacity
and diastolic function are not necessarily covariates. As
these patients are often older and require treatment for
concomitant conditions, endpoints such as quality of life
and functional capacity may be more clinically relevant.
With only 6 trials in this analysis investigating the effect of
treatment on exercise capacity, there is great scope for future
trials to further explore this issue.
Study limitations. While every attempt was made to ex-
tract and collate data from individual studies, there are
inherent gaps in the data stemming from inconsistently
recorded variables and discrepancies in HFpEF diagnostic
criteria. That was particularly the case in relation to diastolic
function data, the modern markers of which (such as E/e=)
are rarely reported. In addition, primary and secondary
outcome measures varied considerably across studies, and
some only assessed smaller endpoints such as quality of life.
In some cases, we were limited, therefore, in our ability to
combine datasets for specific outcomes and can only report
results from individual studies. Compared with mortality
endpoints, trials investigating exercise capacity may also be
more vulnerable to publication bias, with neutral or negative
results evading publication. Finally, an important issue
pertains to the differences in patient demographics between
RCTs and observational trials. Patients in observational
studies were older, more often women, and had a greater
number of comorbidities, likely a result of retrospective
diagnoses based on exclusion of other conditions.
Conclusions
Meta-analysis of drug trials in HFpEF reveals significant
improvement in symptomatic status measured by exercise
capacity in the absence of changes in diastolic function or
mortality benefits. As patients with HFpEF are often older
than their SHF counterparts, improvement of symptoms,
rather than reduction of mortality, may present more
important and pragmatic outcomes. Furthermore, adher-
ence of trial recruitment to endorsed HFpEF criteria and
the utilization of more effective screening tools may provide
a more homogenous study group for future trials.
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